Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-07-24

Atara Biotherapeutics (ATRA)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$1,068,069
AnhCo Nguyen total, FY2025
CEO pay percentile vs peers
CEO-to-median pay ratio
98.75%
Say-on-pay support, latest vote
Companies that benchmark against ATRA
4 companies name ATRA as a compensation peer

Each company listed discloses ATRA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATRA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
AnhCo Nguyen$668,800$390,000$0$0$0$0$9,269$1,068,069
President and Chief Executive Officer
Eric Hyllengren132,00058,500250,949000600,9181,042,367
Former Executive Vice President, Chief Financial Officer and Chief Operating Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
AnhCo Nguyen$1,068,069$1,573,716−505,647
Eric Hyllengren1,042,367926,137+116,230

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
EcoR1 Capital, LLCGreater-than-10% holder2026-05-07A507,407$9$4,744,255CommonForm 4 ↗
Panacea Innovation LtdGreater-than-10% holder2026-05-07D313,446103,165,021CommonForm 4 ↗
AnhCo NguyenDirector2026-05-18D5,241947,845CommonForm 4 ↗
Yanina Grant-HuertaChief Accounting Officer2026-05-18D2,414922,036CommonForm 4 ↗
Matthew K. FustDirector2026-06-09A12,00000CommonForm 4 ↗
William K. HeidenDirector2026-06-09A12,00000CommonForm 4 ↗
Gregory Austin CiongoliDirector2026-06-09A12,00000CommonForm 4 ↗
Brian N. CherryDirector2026-06-11A24,00000CommonForm 4 ↗
Redmile Group, LLCDirector2026-07-22D101,08900Derivative, Class A CommonForm 4 ↗
Redmile Group, LLCDirector2026-07-22D60Common, indirectForm 4 ↗
Redmile Group, LLCDirector2026-07-22A195,211Common, indirectForm 4 ↗
Redmile Group, LLCDirector2026-07-22D38,73500Derivative, Class A CommonForm 4 ↗
Redmile Group, LLCDirector2026-07-22D55,38700Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Eric HyllengrenRSU2025-01-0134,050
03b

Vehicle mix — grant-date fair value by award type

Grant-level vehicle detail not disclosed.

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
AnhCo NguyenRSU30,000$542,700
AnhCo NguyenRSU3,37561,054
AnhCo NguyenRSU5139,280
AnhCo NguyenOption1,15797.75
AnhCo NguyenRSU1502,714
AnhCo NguyenOption281255.25
05

Incentive-plan design — the Compensation Discussion & Analysis

Our philosophy in setting compensation policies for executive officers has two primary objectives: (i) to attract and retain talented and skilled executives by paying for performance; and (ii) to align compensation of our executives with the interests of our stockholders through an appropriate mix of short-term and long-term compensation.

CEO STI target (% of salary)
CEO LTI target (% of salary)
Independent consultantPearl Meyer
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-093,526,41144,4814,53298.75%Passed
20252025-06-102,979,31143,44513,28498.56%Passed
20242024-06-1063,970,4876,810,564350,32190.38%Passed
20232023-05-3171,805,7712,174,272167,12297.06%Passed
20222022-06-2378,488,1472,362,93349,35197.08%Passed
20212021-06-0864,159,4891,216,269175,92598.14%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-06-0998.75%a
20252025-06-1098.56%b
20242024-06-1090.38%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
09

Board fee structure and ownership guideline

Annual cash retainer$45,000
Annual equity retainer$300,000
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)20,000 / 7,500 / 10,000
Stock ownership guideline3x base salary for non-employee directors
10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Atara Biotherapeutics2025AnhCo Nguyen$668,800$0$0$0$1,068,069

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, AnhCo NguyenDEF 14A2026-04-240001193125-26-177285Section “2025 Summary Compensation Table”. As printed: 1,068,069. Filing ↗machine: span 714260–714269
2Section 01, Eric HyllengrenDEF 14A2026-04-240001193125-26-177285Section “2025 Summary Compensation Table”. As printed: 1,042,367. Filing ↗machine: span 719594–719603
3Section 03, Eric Hyllengren RSUDEF 14A2026-04-240001193125-26-177285Section “INFORMATION REGARDING THE BOARD OF DIRECTORS AND CORPORATE GOVERNANCE” · grants of plan-based awards table. Filing ↗machine: t12 · r3 · c1 · span 490602–490608
4Section 07, pay ratio10-K2026-03-160001193125-26-108361Section “CEO Pay Ratio”. As printed: —. Filing ↗
5Section 02, EcoR1 Capital, LLC 2026-05-07Form 42026-05-110000935836-26-000239Insider equity transaction reported since the proxy statement. Filing ↗
6Section 02, Panacea Innovation Ltd 2026-05-07Form 42026-05-110001193125-26-217380Insider equity transaction reported since the proxy statement. Filing ↗
7Section 02, AnhCo Nguyen 2026-05-18Form 42026-05-200000905148-26-002571Insider equity transaction reported since the proxy statement. Filing ↗
8Section 02, Yanina Grant-Huerta 2026-05-18Form 42026-05-200000905148-26-002570Insider equity transaction reported since the proxy statement. Filing ↗
9Section 02, Matthew K. Fust 2026-06-09Form 42026-06-110000905148-26-002920Insider equity transaction reported since the proxy statement. Filing ↗
10Section 02, William K. Heiden 2026-06-09Form 42026-06-110000905148-26-002921Insider equity transaction reported since the proxy statement. Filing ↗
11Section 02, Gregory Austin Ciongoli 2026-06-09Form 42026-06-110000905148-26-002919Insider equity transaction reported since the proxy statement. Filing ↗
12Section 02, Brian N. Cherry 2026-06-11Form 42026-06-150000905148-26-002951Insider equity transaction reported since the proxy statement. Filing ↗
13Section 02, Redmile Group, LLC 2026-07-22Form 42026-07-240001104659-26-086733Insider equity transaction reported since the proxy statement. Filing ↗
14Section 02, Redmile Group, LLC 2026-07-22Form 42026-07-240001104659-26-086733Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Redmile Group, LLC 2026-07-22Form 42026-07-240001104659-26-086733Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Redmile Group, LLC 2026-07-22Form 42026-07-240001104659-26-086733Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Redmile Group, LLC 2026-07-22Form 42026-07-240001104659-26-086733Insider equity transaction reported since the proxy statement. Filing ↗
18Section 06, 2026 voteForm 8-K2026-06-120001213900-26-068264Item 5.07 · say-on-pay result. As reported: 98.75% (votes for as printed: 3,526,411). Filing ↗
19Section 06, 2025 voteForm 8-K2025-06-110001193125-25-139150Item 5.07 · say-on-pay result. As reported: 98.56% (votes for as printed: 2,979,311). Filing ↗
20Section 06, 2024 voteForm 8-K2024-06-110001193125-24-158461Item 5.07 · say-on-pay result. As reported: 90.38% (votes for as printed: 63,970,487). Filing ↗
21Section 01 trend, Δ column (computed)ComputedcomputedΔ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
22Atara Biotherapeutics (subject), Section 10b CEO totalDEF 14A2026-04-240001193125-26-177285CEO total compensation as printed in Atara Biotherapeutics's own proxy. As printed: 1,068,069. Filing ↗machine: span 714260–714269